香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681) 自願公告 訂立戰略合作協議以拓展日本及東南亞市場及 搭建老年人AI數字健康一體化平台 本公告由腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司已於近日與東京生活館株式會社 (Tokyo Lifestyle Co., Ltd)（「Tokyo Lifestyle」或「合作方」）訂立戰略合作協議（「本 協議」）。雙方將圍繞認知障礙數字療法與功能健康品的深度融合，在日本及東南 亞等地區共同探索「線上認知能力檢測及訓練康復+線下功能健康品有機結合」的 一體化平台模式，致力於為老年人搭建AI數字健康一體化平台。 一、合作方介紹 東京生活館 ...

Group 1 - The article highlights the collaboration between Northern Light Venture Capital and Chuangyebang to celebrate the growth of entrepreneurial companies, specifically XSKY and BrainCo, discussing themes of ideals, growth, and values [3][4] - BrainCo, established in 2019, has emerged as a leading digital therapy company, successfully listing on the Hong Kong Stock Exchange in January 2025, becoming the first digital therapy stock in China [10] - The narrative emphasizes the challenges faced by BrainCo, including a period of financial struggle where the team of over thirty had to persevere through difficult times while maintaining their vision [5][6] Group 2 - The article poses questions about the journey of BrainCo, exploring whether their success was due to luck or persistence, and how they navigated through their darkest moments [8] - It discusses the nature of digital therapy, which aims to address serious conditions like Alzheimer's and depression, questioning whether it represents genuine innovation or a potential bubble [8] - The story of BrainCo is framed as an inspiring example for entrepreneurs and those interested in the future of healthcare and technology, illustrating how a company can find hope in despair [8]

Core Viewpoint - The company, Brainstorm Aurora-B (06681), has seen its stock price increase by over 4%, currently trading at 4.83 HKD with a transaction volume of 48.71 million HKD, following the announcement of a strategic partnership with Macau Kiang Wu Hospital to enhance digital health services for cognitive disorders [1] Group 1 - The company’s subsidiary, Brainstorm Aurora Medical Technology (Macau) Limited, has signed a cooperation agreement with Macau Kiang Wu Hospital to provide digital AI technology services for brain health [1] - The partnership aims to establish a comprehensive health management model covering "hospital-community-home" for cognitive disorder screening, assessment, training, and management in the Macau region [1] - The board believes this collaboration sets a benchmark for the group and opens up the Greater Bay Area market, marking the first flagship project for the group’s digital therapy in the Hong Kong-Macau region [1] Group 2 - The collaboration enriches the company's ecosystem alliance with authoritative medical institutions, complementing a recent national-level project partnership with the National Rehabilitation Aids Research Center under the Ministry of Civil Affairs [1] - This initiative aims to promote the standardization and large-scale application of cognitive digital therapies [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 自願公告 與澳門鏡湖醫院簽署腦健康數字AI技術服務合作協議 本公告乃腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願作出，旨在知會本公司股東及潛在投資者本集團於港澳地區之最新業務發展。 本公司董事會（「董事會」）欣然宣佈，本公司之間接全資附屬公司－腦動極光醫學 科技數智（澳門）有限公司（「腦動極光澳門」），已於近期與澳門鏡湖醫院（「鏡湖 醫院」）正式簽署《腦健康數字AI技術服務合作協議》（「該協議」）。雙方將圍繞認 知障礙的數字篩查、評估、訓練及全程健康管理，在澳門地區建立長期戰略合作 關係，共同構建覆蓋「醫院 － 社區 － 家居」的全鏈條腦健康服務新模式（「本次合 作」）。 一、合作背景 董事會認為，本次合作對本集團 ...

Core Viewpoint - The company has entered into a strategic cooperation agreement with Silk Road Technology Co., Ltd. to promote the localization, market promotion, and scientific transformation of cognitive impairment digital therapy products in Malaysia and Southeast Asia [1] Group 1: Strategic Cooperation - The agreement includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia [1] - Silk Road Technology will assist the company in coordinating local approvals, site planning, and equipment importation [1] - The company will provide technical solutions and research support, leading the research and operational aspects [1]

Core Viewpoint - The stock of Brainstorm Cell Therapeutics Inc. (脑动极光-B) experienced a significant increase of nearly 10%, reaching a peak price of 8.14 HKD per share, with a total market capitalization of approximately 10 billion HKD as of January 8, 2026 [1][2]. Group 1: Stock Performance - The stock opened at 7.46 HKD and reached a maximum price of 8.14 HKD, with a closing price of 7.21 HKD the previous day [2]. - The stock's 52-week high is 17.79 HKD, while the 52-week low is 3.51 HKD [2]. - The trading volume was 39.6 million shares, with an external trading volume of 22.58 million and an internal trading volume of 17.02 million [2]. Group 2: Company Developments - Brainstorm Cell Therapeutics announced on January 7 that it has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2]. - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has received approval to establish the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [1][2].

Core Viewpoint - The company, Brainstorm Cell Therapeutics-B (06681), has seen its stock price increase by over 8%, currently trading at 7.75 HKD with a transaction volume of 58.17 million HKD, following the announcement of significant business collaborations aimed at advancing digital therapies for mental health [1] Group 1: Business Collaborations - The company has signed important business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to jointly promote the research and commercialization of digital therapy products for mental health [1] - The collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University has led to the establishment of a key laboratory for precision intelligent diagnosis and treatment of mental disorders in Beijing [1] Group 2: Clinical Applications and Network Expansion - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health hospital and national center for mental disease medicine, to promote the clinical application of digital therapy products for mental health [1] - The recent partnerships further expand the company's presence in core mental health specialty hospitals across the country, creating a comprehensive commercial network from national flagship centers to regional hubs and key specialty hospitals [1]

Group 1 - The core point of the article highlights that Brainstorm Aurora-B (06681) has deposited shares worth HKD 1.959 billion into Guotai Junan (Hong Kong), representing 20.77% of the total shareholding [2] Group 2 - Brainstorm Aurora has recently signed significant business cooperation agreements with Peking University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [3] - The company, in collaboration with Peking University Sixth Hospital and the National Engineering Research Center for Software Engineering at Peking University, has successfully applied for the establishment of the "Beijing Key Laboratory for Precision Intelligent Diagnosis and Treatment of Mental Disorders" [3]

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][4]. Group 1: Collaboration Details - The collaboration with Beijing University Sixth Hospital includes the development of digital therapies and clinical application research, focusing on attention deficit hyperactivity disorder (ADHD) cognitive digital therapy and a precision intelligent diagnosis system for depression [2]. - The research scope encompasses the development of digital therapy products for emotional and behavioral issues across the entire lifecycle, including clinical validation of cognitive digital therapies aimed at improving learning abilities in children with ADHD [2]. - The partnership with Shandong Provincial Mental Health Center involves the development of cognitive screening and intervention systems for mental disorders, as well as methods for capacity training guided by virtual humans [3]. Group 2: Laboratory Establishment - The "Precision Intelligent Diagnosis and Innovation Transformation Key Laboratory for Mental Diseases" has been officially approved, with the company as a core co-construction unit alongside Beijing University Sixth Hospital and the National Engineering Research Center for Software Engineering [3]. - The laboratory will focus on innovation and transformation driven by clinical needs in mental health, integrating clinical medicine, basic research, technology development, and hardware innovation [3]. Group 3: Strategic Positioning - The company has established close commercial cooperation with Beijing Anding Hospital, a top-tier mental health facility, to promote the clinical application of digital mental health therapies [4]. - The recent collaborations further expand the company's network within core mental health specialty hospitals across the country, creating a comprehensive commercial landing network from national flagship centers to regional hubs and key specialty hospitals [4]. - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's first-mover advantage in the digital mental health therapy sector, accelerating product development and commercialization processes [4].

Core Viewpoint - The company has signed significant business cooperation agreements with Beijing University Sixth Hospital and Shandong Provincial Mental Health Center to advance the research and commercialization of digital therapies for mental health [1][2][3]. Group 1: Joint Research Content - The research will focus on developing digital therapies and clinical applications, including the effectiveness of cognitive digital therapies for Attention Deficit Hyperactivity Disorder (ADHD) and a precision intelligent diagnosis system for depression [2]. - The research scope includes developing digital therapy products for emotional and behavioral issues across the entire lifecycle, with clinical validation for various age groups [2][3]. Group 2: Commercial Cooperation Content - The company will collaborate on digital technology services for cognitive disorder diagnosis and treatment, establishing a health management system covering elderly, children, and adults [2][3]. Group 3: Establishment of Key Laboratory - The "Beijing Key Laboratory for Precision Intelligent Diagnosis and Transformation of Mental Disorders" has been officially approved, with the company as a core co-builder [4]. - The laboratory will focus on innovation and transformation driven by clinical needs, integrating clinical medicine, basic research, technology development, and hardware innovation [4]. Group 4: Strategic Importance - The board believes that the implementation of these cooperation agreements and the approval of the key laboratory will strengthen the company's pioneering advantage in the field of digital mental health therapies, accelerating product development and commercialization [5]. - The company aims to continue partnerships with top medical institutions to build a nationwide integrated digital mental health service system [5].